Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced on 4/17/19 the initiation of pre-clinical studies for BMC-121 & BMC-127, two rationally-designed microbial consortia, in its therapeutic immuno-oncology program. The program aims to improve current cancer therapies by modulating patients' response to immune checkpoint blockade across various cancer types through alterations of the patients' gut microbiome.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,